Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/2/2025 | $24.00 | Equal-Weight | Morgan Stanley |
| 12/13/2024 | $28.00 | Outperform | Wolfe Research |
| 12/3/2024 | $23.00 | Equal-Weight | Morgan Stanley |
| 4/22/2024 | Outperform | Exane BNP Paribas | |
| 11/1/2023 | $39.00 → $29.00 | Buy → Hold | Jefferies |
| 9/26/2023 | $33.00 | Overweight | Stephens |
| 9/19/2023 | Market Outperform | CJS Securities | |
| 8/24/2023 | $34.00 | Overweight → Equal-Weight | Morgan Stanley |
SCHEDULE 13G/A - Stevanato Group S.p.A. (0001849853) (Subject)
6-K - Stevanato Group S.p.A. (0001849853) (Filer)
6-K - Stevanato Group S.p.A. (0001849853) (Filer)
Company delivers 9% revenue growth, record revenue from high-value solutions, expanded margins, and maintains fiscal year 2025 guidance Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the third quarter of 2025. Third Quarter 2025 Highlights (comparisons to prior-year period) Revenue increased 9% (11% on a constant currency basis) to €303.2 million. High-value solutions represented a record 49% of total revenue. Gross profit margin increased 240 basis points to 29.2%. Diluted earnings per share were
Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced that it will participate in two upcoming investor conferences. Monday, November 17, 2025, at 8:40 a.m. ET - The 7th Annual Wolfe Research Healthcare Conference in New York City Wednesday, November 19, 2025, at 11:00 a.m. GMT - The Jefferies Global Healthcare Conference in London A live webcast of each event will be available on the Company's website at www.stevanatogroup.com under the "Investors" section. Replays will remain available for approximately 90 days after each event.
Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the third quarter of 2025 on Thursday, November 6, 2025, at 6:30 a.m. (ET). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (ET) on Thursday, November 6, 2025, to discuss financial results. During the call, management will refer to a slide presentation which will be available on the morning of the call on the "Financial Results" page under the Company's Investor Relations section of its website. Pr
Morgan Stanley resumed coverage of Stevanato Group S.p.A. with a rating of Equal-Weight and set a new price target of $24.00
Wolfe Research initiated coverage of Stevanato Group S.p.A. with a rating of Outperform and set a new price target of $28.00
Morgan Stanley resumed coverage of Stevanato Group S.p.A. with a rating of Equal-Weight and set a new price target of $23.00
-All Resolutions Proposed to Shareholders Passed- Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries today announced that all resolutions proposed to the Shareholders at the Annual General Meeting of Shareholders ("AGM") held virtually on May 22, 2024, have passed. Details of the resolutions submitted to, and approved by, the AGM are included in the explanatory report prepared by the Board of Directors of the Company, which is available on the Company's corporate website at https://ir.stevanatogroup.com/. Shareholders approved, among other things, th
Strengthening corporate leadership aims to drive operational efficiencies and standardization of global processes. Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life science industries, today announced the appointment of Ugo Gay as its new Chief Operations Officer (COO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240404727049/en/Ugo Gay appointed as Chief Operations Officer of Stevanato Group (Photo: Business Wire) The addition of Ugo Gay underscores Stevanato Group's unwavering commitment to driving opera
The appointment bolsters company's commitment to growth in the region Stevanato Group, a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, today announced the appointment of Riccardo Butta to the role of President, Americas. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220202005514/en/Riccardo Butta (Photo: Business Wire) The appointment of a dedicated executive to lead the Company's long-term strategy in the Americas is indicative of the growing regional demand trends and the Company's commitment to broaden its footprint, accelerate i
SC 13G/A - Stevanato Group S.p.A. (0001849853) (Subject)
SC 13G/A - Stevanato Group S.p.A. (0001849853) (Subject)
SC 13G - Stevanato Group S.p.A. (0001849853) (Subject)
Company delivers 9% revenue growth, record revenue from high-value solutions, expanded margins, and maintains fiscal year 2025 guidance Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the third quarter of 2025. Third Quarter 2025 Highlights (comparisons to prior-year period) Revenue increased 9% (11% on a constant currency basis) to €303.2 million. High-value solutions represented a record 49% of total revenue. Gross profit margin increased 240 basis points to 29.2%. Diluted earnings per share were
Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the third quarter of 2025 on Thursday, November 6, 2025, at 6:30 a.m. (ET). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (ET) on Thursday, November 6, 2025, to discuss financial results. During the call, management will refer to a slide presentation which will be available on the morning of the call on the "Financial Results" page under the Company's Investor Relations section of its website. Pr
Company delivers 8% revenue growth, expanded margins, and maintains fiscal year 2025 guidance Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the second quarter of 2025. Second Quarter 2025 Highlights (comparisons to prior-year period) Revenue increased 8% to €280.0 million, and high-value solutions represented 42% of total revenue. Gross profit margin increased 210 basis points to 28.1%. Diluted earnings per share were €0.11; adjusted diluted earnings per share were €0.11. Adjusted EBITDA mar